Related Experiment Video
Updated: Jun 8, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Intermittent androgen suppression for prostate cancer
Nicholas C Buchan1, S Larry Goldenberg
1Department of Urologic Sciences and Vancouver Prostate Center, University of British Columbia, 2775 Laurel Street, Vancouver, BC V5Z1M9, Canada.
Nature Reviews. Urology
|September 16, 2010
Summary
Intermittent androgen suppression (IAS) offers similar prostate cancer outcomes to continuous therapy but with fewer side effects and lower costs. Further research is ongoing to optimize patient selection and treatment protocols for this promising approach.
Area of Science:
- Oncology
- Urology
- Clinical Trials
Background:
- Androgen deprivation therapy (ADT) is a standard prostate cancer treatment, but its optimal application remains debated.
- Intermittent androgen suppression (IAS) emerged as an alternative to continuous ADT to mitigate side effects and costs.
- Preclinical data suggested IAS might delay androgen independence, prompting clinical investigation.
Purpose of the Study:
- To evaluate the efficacy and safety of intermittent androgen suppression (IAS) compared to continuous androgen suppression in prostate cancer management.
- To assess the impact of IAS on adverse effects, quality of life, and treatment costs.
- To identify unresolved questions and future research directions for IAS in advanced prostate cancer.
Main Methods:
- Review of preclinical evidence and clinical phase II and III trials comparing IAS with continuous androgen suppression.
- Analysis of outcomes including time to castration resistance and cancer-specific survival.
- Assessment of patient-reported quality of life and cost-effectiveness.
Main Results:
- IAS demonstrates comparable efficacy to continuous androgen suppression regarding time to castration resistance and cancer-specific survival.
- IAS offers significant advantages in reducing adverse effects and improving quality of life.
- IAS presents a more cost-effective treatment option compared to continuous ADT.
Conclusions:
- Intermittent androgen suppression is a viable and promising treatment option for advanced prostate cancer, offering comparable efficacy with improved tolerability and cost-effectiveness.
- Key questions regarding patient selection, optimal treatment duration, and defining disease progression require further investigation through ongoing clinical trials.
- Men with advanced prostate cancer eligible for ADT should be informed about IAS as a potentially beneficial, albeit currently experimental, treatment choice.
Related Concept Videos
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...